News

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.

Follow-up to BALATON/COMINO indicates maintained improvement in best-corrected visual acuity and central subfield thickness 72 weeks after treatment.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study draws correlative connection between semaglutide and nonarteritic anterior ischemic optic neuropathy, more data required to show causation.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

HCPLive spoke with Levine about what is moving in the psychiatry pipeline and what is to come.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

Research presents a correlation between the index and age-related macular degeneration and suggests a causal relationship.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Aquestive’s Anaphylm study showed positive pharmacokinetic results in children and adolescents, supporting its FDA submission.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

March Allergy Updates: FDA approved the first biosimilar for omalizumab, epicutaneous and oral immunotherapy trials showed promise, and experts discussed allergy trends.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.

The study proves that cataract, glaucoma, and age-related eye disease can be exacerbated by exposure to several common pollutants simultaneously.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.